Shanghai Medicilon Inc.

  In the field of   immunotherapy , CD73, an immune regulatory molecule, has attracted much attention in recent years.  As an important component of the tumor microenvironment, CD73 plays an important role in regulating immune responses, inhibiting immune cell activity, and promoting tumor growth and angiogenesis.  Targeted therapy against CD73 has become a target pursued by researchers.  Recently, the ADC project HB0052 of Shanghai Huaota Biopharmaceutical Co., Ltd. (hereinafter referred to as "Huaota") was approved by the FDA to enter clinical trials. Huaota has long been focused on the research, development and production of new biological drugs in the fields of tumors, autoimmune diseases and fundus lesions.  The company has a rich product pipeline and currently has more than 20 research projects, many of which have entered the clinical research stage and are undergoing clinical trials in the United States, New Zealand and China.  What competitiven...

  Recently, Shanghai Huaota Biopharmaceutical Co., Ltd. (Huaota) received a notification from the US FDA, agreeing that the third-generation antibody drug conjugate (ADC) project HB0052 developed by the company targeting the CD73 antigen will enter clinical trials.  This is the first antibody conjugate drug project approved by Huaota Biotech to enter clinical trials by the FDA. As a partner of Huaota, Shanghai Medicilon Inc. (Medicilon) relied on its antibody drug conjugate R&D service platform and its professional technical capabilities and rich project experience to provide HB0052 with R&D of the drug metabolism and safety evaluation tests that complied with GLP standards to ensure high-quality and efficient advancement. Medicilon Antibody Drug Conjugate R&D Service Platform  Pressing the "Accelerator Button" for ADC Drug Development As one of the rare one-stop biopharmaceutical preclinical R&D service platforms in China, Medicilon has established an...